The Cooper Companies, Inc. (COO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2,431 | 2,923 | 3,308 | 3,593 | 3,895 | 4,092 | 4,237 | 4,239 |
| Operating profit | $m | 683 | 545 | ||||||
| Net profit | $m | 238 | 2,945 | 386 | 294 | 392 | 375 | 570 | 913 |
| EPS reported | $ | 1.87 | 2.93 | ||||||
| Operating cashflow per share | $ | 3.98 | 4.89 | ||||||
| Capex per share | $ | 1.81 | 1.97 | ||||||
| FCF per share | $ | 2.17 | 2.92 | ||||||
| Free cash flow | $m | 434 | 678 | ||||||
| Net debt | $m | 2,430 | 2,390 | ||||||
| Book value equity | $m | 8,239 | 8,328 | ||||||
| Book value per share | $ | 41.19 | 43.06 | ||||||
| Number of shares | m | 200 | 193.4 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 37.39 | 46.93 | ||||||
| P/B LTM | x | 1.70 | 1.68 | ||||||
| P/S LTM | x | 3.42 | 3.30 | ||||||
| P/FCF LTM | x | 32.24 | 20.62 | ||||||
| EV/EBITDA LTM | x | 15.81 | 18.30 | ||||||
| EV/Sales LTM | x | 4.07 | 3.76 | ||||||
| Earnings Yield LTM | % | +2.67% | +2.13% | ||||||
| FCF Yield | % | +3.10% | +4.85% | ||||||
| Quality | |||||||||
| ROE | % | +4.55% | +2.84% | ||||||
| ROIC | % | +3.98% | +2.52% | ||||||
| Operating margin | % | +16.69% | +11.77% | ||||||
| Gross margin | % | +60.67% | +64.37% | ||||||
| FCF/Sales | % | +10.60% | +13.46% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -4.59% | +49.49% | ||||||
| Sales Growth YoY | % | +5.06% | +8.77% | ||||||
| Net Income Growth YoY | % | -4.44% | +45.37% | ||||||
| FCF Growth | % | +50.54% | +135.33% | ||||||
| Operating Profit Growth | % | -3.23% | -22.83% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.16 | 0.27 | ||||||
| Net Debt/EBITDA | x | 2.54 | 2.68 | ||||||
| EBIT/Net interest | x | 6.83 | 5.35 | ||||||
| Net debt/market cap | % | +18.18% | +18.13% | ||||||
| Net debt/Equity | x | 0.29 | 0.29 | ||||||
| Gross debt/equity | x | 0.34 | 0.31 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free